OABIW NASDAQ
Credit Risk of going bust: lower than 56% of companies Debt: 2.7% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down 99.7%), OmniAb, Inc. would be worth roughly what it owes.
Total debt $18.9M against a stock market value of $670.2M.
Distance to default 5.73 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $9.5M (short-term plus half of long-term), stock volatility 71.9%; Altman Z'' 7.26. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
EmeryVille, CA 94608
US
OmniAb, Inc., established in 2012 and headquartered in Emeryville, California, operates as a biotechnology firm focused on pioneering technologies for the discovery of therapeutic antibodies within the United States. The company's flagship offering is its OmniAb platform, which provides industry collaborators with access to a broad spectrum of antibody repertoires and advanced screening techniques. This capability empowers partners to develop next-generation therapeutic agents. At the heart of the OmniAb platform are proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse. These animals have been genetically engineered to produce antibodies featuring human sequences, thereby streamlining the path to creating human therapeutic candidates. Beyond this core offering, OmniAb also addresses specific industry needs with specialized animal models: OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken) facilitate bispecific antibody applications through a shared light chain mechanism. Additionally, OmniTaur provides a solution for challenging targets by leveraging the distinctive structural characteristics of cow antibodies.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Gotwals Philip J | M-Exempt | 13,333 | — | 2026-04-21 |
| Gotwals Philip J | M-Exempt | 13,333 | — | 2026-04-21 |
| Crouse Steven C. | M-Exempt | 13,333 | — | 2026-04-21 |
| Crouse Steven C. | M-Exempt | 13,333 | — | 2026-04-21 |
| FOEHR MATTHEW W | M-Exempt | 36,459 | — | 2026-04-07 |